Patents by Inventor Alison J. Brownlie

Alison J. Brownlie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
    Publication number: 20110060014
    Abstract: The use of screening assays based on the role of human stearoyl-CoA desaturase-1 (“hSCD1”) in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, is disclosed. Also disclosed are conventions useful in the prevention and/or treatment of such diseases.
    Type: Application
    Filed: September 9, 2010
    Publication date: March 10, 2011
    Inventors: Michael R. Hayden, Alison J. Brownlie, James M. Ntambi, Makoto Miyazaki, Mark P. Gray-Keller, Alan D. Attie
  • Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
    Patent number: 7816075
    Abstract: The use of screening assays based on the role of human stearoyl-CoA desaturase-1 (“hSCD1”) in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, is disclosed. Also disclosed are conventions useful in the prevention and/or treatment of such diseases.
    Type: Grant
    Filed: July 11, 2005
    Date of Patent: October 19, 2010
    Assignees: Xenon Pharmaceuticals Inc., Wisconsin Alumni Research Foundation
    Inventors: Michael R. Hayden, Alison J. Brownlie, James M. Ntambi, Makoto Miyazaki, Mark P. Gray-Keller, Alan D. Attie
  • Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
    Patent number: 7696151
    Abstract: The use of screening assays based on the role of human stearoyl-CoA desaturase-1 (“hSCD1”) in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, is disclosed. Also disclosed are conventions useful in the prevention and/or treatment of such diseases.
    Type: Grant
    Filed: July 11, 2005
    Date of Patent: April 13, 2010
    Assignees: Xenon Pharmaceuticals Inc., Wisconsin Alumni Research Foundation
    Inventors: Michael R. Hayden, Alison J. Brownlie, James M. Ntambi, Makoto Miyazaki, Mark P. Gray-Keller, Alan D. Attie
  • Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5
    Patent number: 7435559
    Abstract: A cDNA encoding a novel human stearoy-CoA desaturase (dubbed “hSCD5”) as well as vectors and cells comprising such polynucleotide are disclosed. Also described are assay methods for determining the ability of small molecules and other chemical agents to increase or decrease he enzymatic activity and/or gene expression level of hSCD5 as well as processes for using such agents to treat, prevent or diagnose a variety of diseases and other conditions.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: October 14, 2008
    Assignee: Xenon Pharmaceuticals Inc.
    Inventor: Alison J. Brownlie
  • Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5
    Patent number: 7232662
    Abstract: A cDNA encoding a novel human stearoy-CoA desaturase (dubbed “hSCD5”) as well as vectors and cells comprising such polynucleotide are disclosed. Also described are assay methods for determining the ability of small molecules and other chemical agents to increase or decrease the enzymatic activity and/or gene expression level of hSCD5 as well as processes for using such agents to treat, prevent or diagnose a variety of diseases and other conditions.
    Type: Grant
    Filed: September 26, 2001
    Date of Patent: June 19, 2007
    Assignee: Xenon Pharmaceuticals Inc.
    Inventor: Alison J. Brownlie
  • Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
    Patent number: 6987001
    Abstract: The use of screening assays based on the role of human stearoyl-CoA desaturase-1 (“hSCD1”) in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, is disclosed. Also disclosed are conventions useful in the prevention and/or treatment of such diseases.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: January 17, 2006
    Assignees: Xenon Pharmaceuticals Inc., Wisconsin Alumni Research Foundation, University of British Columbia
    Inventors: Michael R. Hayden, Alison J. Brownlie, James M. Ntambi, Makoto Miyazaki, Mark P. Gray-Keller, Alan D. Attie
  • Methods and compositions employing a novel stearoyl-coa desaturase-hscd5
    Publication number: 20040091988
    Abstract: A cDNA encoding a novel human stearoy-CoA desaturase (dubbed “hSCD5”) as well as vectors and cells comprising such polynucleotide are disclosed. Also described are assay methods for determining the ability of small molecules and other chemical agents to increase or decrease he enzymatic activity and/or gene expression level of hSCD5 as well as processes for using such agents to treat, prevent or diagnose a variety of diseases and other conditions.
    Type: Application
    Filed: October 2, 2003
    Publication date: May 13, 2004
    Inventor: Alison J. Brownlie
  • Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
    Publication number: 20030157552
    Abstract: The use of screening assays based on the role of human stearoyl-CoA desaturase-1 (“hSCD1”) in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, is disclosed. Also disclosed are conventions useful in the prevention and/or treatment of such diseases.
    Type: Application
    Filed: February 23, 2001
    Publication date: August 21, 2003
    Inventors: Michael R. Hayden, Alison J. Brownlie, James M. Ntambi, Makoto Miyazaki, Mark P. Gray-Keller, Alan D. Attie